Kamiren (Doxazosin)

Doxazosin, the active ingredient in Kamiren, is an alpha-1 adrenergic blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure and to relieve urinary obstruction caused by benign prostatic hyperplasia in adult patients.

GNH USA supplies Kamiren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Doxazosin is indicated for conditions that involve alpha‑1 mediated vascular tone or smooth‑muscle contraction.

- Hypertension: reduces systolic and diastolic blood pressure by decreasing peripheral vascular resistance. - Benign prostatic hyperplasia (BPH): relaxes prostate and bladder neck smooth muscle, improving urinary flow and reducing urgency.

Doxazosin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness, especially on standing. - Headache. - Fatigue or general weakness. - Nasal congestion. - Peripheral edema. - Nausea.

Serious or Rare Side Effects: - Marked hypotension or syncope. - Priapism. - Severe allergic reactions, including rash or angioedema. - Hepatic dysfunction. - Rapid heart rate (tachycardia). - Chest pain or myocardial ischemia.

Before initiating therapy, clinicians should consider several safety measures.

- Blood pressure monitoring: check supine and standing readings to detect orthostatic changes. - Cardiovascular assessment: evaluate for existing heart disease or arrhythmias. - Hepatic function: use caution in patients with liver impairment. - Concomitant antihypertensives: adjust doses to avoid excessive hypotension. - Discontinuation: taper gradually rather than stopping abruptly. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Doxazosin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): may cause severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase plasma concentrations. - Other potent antihypertensives (e.g., clonidine, nitroprusside): additive blood‑pressure lowering effect.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance orthostatic hypotension. - NSAIDs: can blunt antihypertensive response. - Beta‑blockers or calcium‑channel blockers: monitor for combined cardiovascular effects. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug levels. - Lithium: monitor serum lithium concentrations.